BPH capital raising to support development of PEP11

|

Published 03-FEB-2021 11:06 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

BPH Energy Limited (ASX:BPH; BPHAO) has completed a share placement to sophisticated and professional investors that will provide the capacity to raise $9 million.

While the issue price of 13 cents represents a discount of about 20% to the 10-day volume-weighted average share price (VWAP), it should be noted that in the last week of December the company’s shares were trading as low as 3.4 cents.

The proceeds of the placement will be used by BPH primarily to invest in Advent Energy Limited.

BPH Energy Ltd’s investee company, Advent Energy Ltd through its wholly-owned subsidiary Asset Energy Pty Ltd (Asset), has signed a Preliminary Well Services Agreement with Add Energy for the drilling of the Baleen prospect, offshore New South Wales.

Advent Energy holds a strong portfolio of conventional and non-conventional near-term development and exploration assets spanning highly prospective acreage onshore and offshore Australia in proven petroleum basins.

The funds proposed to be invested by BPH will be used by Advent to progress well planning, engineering and environmental approvals for drilling at the Baleen drill target in the PEP11 offshore permit in NSW (see above).

It is planned that approximately $5.75 million of the capital raised will be used for this purpose.

Commenting on the capital raising, BPH managing director David Breeze said, “The company is pleased to receive funding from a range of investors including existing and new shareholders, and others who participated in the placement through Everblu Capital and 62 Capital”.

NOPTA close to decision regarding permit conditions for PEP11

BPH has previously advised it will underwrite and invest in Advent and will increase BPH’s shareholding from 22% to approximately 33% (subject to any required approvals or via an underwriting of an offer by BPH).

Advent has submitted to the National Offshore Petroleum Titles Administrator (NOPTA) an application to change the current PEP11 permit conditions in order for it to proceed with the drilling.

Advent, through its wholly-owned subsidiary Asset Energy Pty Ltd (Asset), holds an 85% interest and is operator of the PEP11 permit.

Bounty Oil and Gas NL (ASX: BUY) holds the remaining 15%.

The NOPTA application is in the final decision phase.

Management also expects to use $500,000 of the placement proceeds to increase its shareholding in Cortical Dynamics Limited (Cortical) from 16% to 18%, enabling further development of its Brain Anesthesia Response Monitor (BARM).



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X